Almost one half of surveyed German gastroenterologists and 37% of rheumatologists consider themselves to be very or extremely familiar with biosimilars, but less than one-third of these physicians are aware that Inflectra and Remsima have been approved for the same indications as Remicade
In Europe, Remicade
is indicated for the treatment of rheumatic arthritis, adult Crohn's disease, pediatric Crohn's disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, ankylosing spondylitis and psoriasis.
At the heart of the dispute is the merger of Merck and Schering-Plough, which was cleverly designed to enable Merck to retain the Remicade
Tanabe speculates that the launch of Methotrexate will accelerate the use of Remicade
in the future.
Comment: In the two studies of 728 patients with moderately to severely active ulcerative colitis who were not responding to other treatments, including steroids and immunosuppressives, the rates of clinical responses, sustained clinical responses, clinical remissions, and mucosal healing were significantly greater among those treated with Remicade
at 30 weeks.
is now indicated for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
reduces inflammation by binding to and neutralizing TNF-[alpha], one of the key cytokines that is overproduced and lead to inflammation in RA, Crohn's, and other autoimmune diseases.
Detailed information on Remicade
(infliximab) including product description, safety and efficacy profiles as well as a SWOT analysis.
Key Topics Covered: EXECUTIVE SUMMARY LESSONS FROM LAUNCHED BIOGENERIC PROGRESS IN JAPAN SINCE 2009 REGULATORY APPROVAL REQUIREMENT AND REIMBURSEMENT SCENARIO FOR COMPLEX MAB BIOSIMILAR IN JAPAN REMICADE
(INFLIXIMAB) BIOSIMILAR - JAPAN MARKET DYNAMICS- For volume market share- Does it repeat the story of Norway?
produced a more than $5 billion in combined revenue last year, according to the data research firm IMS Health Inc.
A day before Amgen released the study results, Johnson & Johnson said its arthritis drug Remicade
improved symptoms of the skin disorder psoriasis in 88 percent of patients receiving the highest dose of the drug.
, a biologic agent indicated for rheumatoid arthritis and Crohn's disease, has been associated with tuberculosis and other opportunistic infections, including histoplasmosis, listeriosis, and pneumocystosis, according to an Oct.
Abbott's Humira (adalimumab) has made substantial inroads in the Crohn's disease (CD) market despite launching nine years after the market leader, Janssen Biotech's Remicade
(infliximab), and lacking labeling for CD that is as expansive as that of Remicade
The recommended dose of REMICADE
in AS is 5 mg/kg given as an IV induction regimen at 0, 2 and 6 weeks followed by a 5 mg/kg maintenance regimen every 6 weeks in the United States or every 6-8 weeks in the European Union.
The company manufactures Remicade
, a therapy that combats Crohn's disease and rheumatoid arthritis.